Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JM-010 in Parkinson's Disease Patients With Dyskinesia
NCT04377945Phase 2Terminated
- Sponsor
- Bukwang Pharmaceutical
- Start
- Apr 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of buspirone, zolmitriptan in levodopa-induced dyskinesia (LID), sponsored by Bukwang Pharmaceutical. Started Apr 2021; status: terminated.
02
Drugs
buspironezolmitriptan
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT04377945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04377945.